参考文献/References:
[1]Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.[2]Clevers H,Nusse R.Wnt/beta-catenin signaling and disease[J].Cell,2012,149(6):1192-1205.[3]Wang L,Leung S,Talhouk A.Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome[J].Histopathology,2019,74(3):452-462.[4]杨尊敬,杜先玲.WNT1、β-catenin、PD-L1蛋白在上皮性卵巢浆液性癌中的表达及临床意义[J].癌症进展,2019,17(17):2079-2082.[5]Wu G,Xu G,Schulman BA.Structure of a beta-TrCP1-Skp1-beta-catenin complex:destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase[J].Mol Cell,2003,11(6):1445-1456.[6]Nusse R,Clevers H.Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities[J].Cell,2017,169(6):985-999.[7]Zhang Y,Wang X.Targeting the Wnt/β-catenin signaling pathway in cancer[J].J Hematol Oncol,2020,13(1):165.[8]Shen G,Gao Q,Liu F.The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab[J].Biochem Biophys Res Commun,2020,526(3):685-691.[9]Zhang H,Sun D,Qiu J,et al.SFRP1 inhibited the epithelial ovarian cancer through inhibiting Wnt/β-catenin signaling[J].Acta Biochim Pol,2019,66(4):393-400.[10]Wang Y,Cao J,Liu W,et al.Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin[J].J Biol Chem,2019,294(48):18306-18323.[11]Croce S,Lesluyes T,Delespaul L,et al.GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT):A novel CTNNB1 rearrangement[J].Genes Chromosomes Cancer,2019,58(3):155-163.[12]Liao YM,Song Y,Zhou Y,et al.SOX17,β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression[J].Cancer Gene Ther,2020,27(3-4):256-263.[13]Dong P,Zhang S,Zhang X,et al.PCNP promotes ovarian cancer progression by accelerating β-catenin nuclear accumulation and triggering EMT transition[J].J Cell Mol Med,2020,24(14):8221-8235.[14]杨宏毅.TNKS1通过Wnt/β-catenin信号通路调控卵巢癌发生发展的作用与机制[D].广州:南方医科大学,2020.[15]冯姗姗,郑洪,王凯.沉默LOXL2表达对卵巢癌SKOV3细胞生长及Wnt/β-catenin信号通路的影响[J].郑州大学学报(医学版),2020,55(1):41-44.[16]Mehdi S,Droit A,Bachvarov D.LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway[J].Int J Mol Sci,2020,21(5):1848.[17]邓琳.cox2、wnt3a和β-catenin在子宫内膜癌及卵巢癌中的表达水平及对诊断的提示作用[D].北京:北京协和医学院,2020.[18]Zhuang XH,Liu Y,Li JL.Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway[J].Biosci Rep,2019,39(8):BSR20190906.[19]Zhou Y,Jin Z,Wang,C.Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p[J].Biomed Pharmacother,2019(120):109449.[20]Liu L,Ning Y,Yi J.miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression[J].Biomed Pharmacother,2020(125):109865.[21]Liu HR,Zhao J.Effect and mechanism of miR-217 on drug resistance,invasion and metastasis of ovarian cancer cells through a regulatory axis of CUL4B gene silencing/inhibited Wnt/β-catenin signaling pathway activation[J].Eur Rev Med Pharmacol Sci,2021,25(1):94-107.[22]陈茹,苏莹,柳江.淫羊藿苷通过Wnt/β-catenin信号通路对卵巢癌细CAOV增殖的影响[J].医学研究杂志,2019,48(3):131-134.[23]龚建明,周莹巧,林琪.羟基红花黄色素A通Wnt/β-catenin信号通路抑制卵巢癌生长[J].医学研究杂志,2019,48(10):44-49.[24]Zhou B,Wang C,Liu X.Combination of nigericin with cisplatin enhances the inhibitory effect of cisplatin on epithelial ovarian cancer metastasis by inhibiting slug expression via the Wnt/beta-catenin signalling pathway[J].Oncol Lett,2021,22(4):700.
相似文献/References:
[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,31(23):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Medical Information,2019,32(23):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,32(23):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(23):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,32(23):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(23):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]许晓燕,冯 群,夏 嫱.Wnt/β-catenin信号通路在宫颈癌发生发展中的研究进展[J].医学信息,2021,34(05):1.[doi:10.3969/j.issn.1006-1959.2021.05.001]
XU Xiao-yan,FENG Qun,XIA Qiang.Research Progress of Wnt/β-catenin Signaling Pathway in the Occurrence and Development of Cervical Cancer[J].Medical Information,2021,34(23):1.[doi:10.3969/j.issn.1006-1959.2021.05.001]
[8]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Medical Information,2019,32(23):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[9]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Medical Information,2019,32(23):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[10]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Medical Information,2020,33(23):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]